Cesca Therapeutics Inc. focuses on the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine in the United States and internationally. The company develops and manufactures automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. Its products include SurgWerks system, a proprietary system comprised of the SurgWerks processing platform, including devices and analytics, and indication-specific SurgWerks procedure kits for use in regenerative stem cell therapy at the point of care for vascular and orthopedic diseases; CellWerks system, a proprietary cell processing system with associated analytics for intra-laboratory preparation of adult stem cells from bone marrow or blood; and AutoXpress system, a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood. The company also offers MarrowXpress system, a derivative product of the AXP and its accompanying sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow; BioArchive system, an automated cryogenic device used by cord blood banks for the cryopreservation and storage of cord blood stem cell concentrate for future use; and manual disposables bag sets for use in the processing and cryogenic storage of cord blood. In addition, it provides cell manufacturing and banking services. The company was formerly known as ThermoGenesis Corp. and changed its name to Cesca Therapeutics Inc. in February 2014. Cesca Therapeutics Inc. was founded in 1986 and is headquartered in Rancho Cordova, California.
